FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formula
,
where the carbon atom denoted * is in R- or S-configuration; X is a concentrated bicyclic carbocycle or heterocycle selected from a group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, indazolyl, indolyl, benzooxazolyl, benzothiazolyl, indenyl, indanyl, dihydrobenzocycloheptenyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, quinoxalinyl, 2H-chromenyl, imidazo[1.2-a]pyridinyl, pyrazolo[1.5-a]pyridinyl, and condensed bicyclic carbocycle or condensed bicyclic heterocycle, optionally substituted with substitutes (1 to 4) which are defined below for R14; R1 is H, C1-C6-alkyl, C3-C6-cyclalkyl, C1-C3-alkyl, substituted OR11, -NR9R10 or -CN; R2 is H, C1-C6-alkyl, or gem-dimethyl; R3 is H, -OR11, C1-C6-alkyl or halogen; R4 is H, halogen, -OR11, -CN, C1-C6-alkyl, C1-C6-alkyl, substituted -NR9R10, C3-C6-cycloalkyl, substituted -NR9R10, C(O)R12; or R4 is morpholinyl, piperidinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, isoxazolyl, pyrrolidinyl, piperazinyl, 2-oxo-2H-pyridinyl, [1.2.4]triazolo[4.3-a]pyridinyl, 3-oxo-[1.2.4]triazolo[4.3-a]pyridinyl, quinoxalinyl, which are optionally substituted with substitutes (1 to 4) which are defined below for R14; R5 is H or C1-C6-alkyl; R6 is H, C1-C6-alkyl, or -OR11; R7 is H; R8 is H, -OR9, C1-C6-alkyl, -CN; R9 is H or C1-C4-alkyl; R10 is H or C1-C4-alkyl; or R9 and R10 taken together with the nitrogen atom to which they are bonded form morpholine; R11 is H, C1-C4-alkyl; R12 is C1-C6-alkyl; R14 in each case is independently selected from a substitute selected from a group consisting of halogen, -OR11, -NR11R12, C1-C6-alkyl, which is optionally substituted with 1-3 substitutes, in each case independently selected from a group consisting of C1-C3-alkyl, aryl; or to pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition, to a method of obtaining formula (I) compounds, as well as to a method of treating disorders.
EFFECT: obtaining new biological active compounds having norepinephrine, dopamine and serotonin reuptake selective inhibitory activity.
90 cl, 162 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL INDOLE AND PYRROLE COMPOUNDS, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2014 |
|
RU2693404C2 |
| AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LYPASE INHIBITORS | 2010 |
|
RU2549547C2 |
| INDOLE AND INDAZOLE COMPOUNDS AS CELLULAR NECROSIS INHIBITORS | 2008 |
|
RU2437883C1 |
| INDANONE DERIVATIVE, ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ENANTIOMER, METHOD FOR PRODUCING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT AND APPLICABLE FOR PREVENTING OR TREATING VIRAL DISEASE | 2012 |
|
RU2574591C2 |
| AZETIDINYL DIAMIDES AS MONOACYLGLICEROL LIPASE INHIBITORS | 2010 |
|
RU2569298C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
| SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2404972C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| THIENOPYRIMIDINE COMPOUNDS AND THEIR APPLICATION | 2004 |
|
RU2331648C2 |
